focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Share News (SYNC)

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 113.00
Bid: 112.60
Ask: 113.00
Change: 5.40 (5.02%)
Spread: 0.40 (0.355%)
Open: 107.00
High: 113.00
Low: 107.00
Prev. Close: 107.60
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DIRECTOR DEALINGS SUMMARY: IAG Chair And Director Spend EUR1.2 Million

Thu, 05th Mar 2020 15:41

(Alliance News) - The follow is a round-up of share dealings by UK company directors and managers announced on Thursday and not separately reported by Alliance News:

----------

International Consolidated Airlines Group SA - Non-Executive Chair Antonio Vazquez Romero buys 84,000 shares at EUR5.34, worth EUR448,896, and Non-Executive Director Francisco Javier Ferran Larraz buys 144,000 at EUR5.22 average price, worth GBP751,968. The EUR1.2 million in purchases were made on Tuesday.

----------

Anexo Group PLC - Executives sell GBP4.4 million in shares on Tuesday, all at 150 pence per shares, "in response to institutional demand". Executive Chair Alan Sellers and Bond Turner Managing Director Samantha Moss each sell 1.3 million shares, while Sales Director Tina Slater sells 290,000. Sellers now holds 36.4 million shares, a 33% holding, Moss 37.4 million for 34%, and Slater 7.4 million for 6.7%.

----------

Syncona Ltd - Non-Executive Director Thomas Henderson sells 1.0 million shares, via Farla Ltd, at GBP2.47, worth GBP2.5 million, on Tuesday. Syncona has a market capitalisation of GBP1.62 billion.

----------

London Stock Exchange Group PLC - Waqas Samad, director of information services & chief executive officer of FTSE Russell, sells 20,890 shares at GBP79.00, worth GBP1.7 million. Non-Executive Director Val Rahmani buys 1,129 shares at GBP79.27, worth GBP89,499. Both on Wednesday.

----------

Elad Ben Izhak - Co-Founder Elad Ben Izhak buys 53,000 shares at GBP9.50, worth GBP503,500, on Tuesday.

----------

Elementis PLC - Chief Financial Officer Ralph Hewins buys 15,034 shares at GBP1.00, worth GBP15,000, on Wednesday.

----------

Tyman PLC - Non-Executive Director Paul Withers buys 25,000 shares at GBP2.54, worth GBP63,488, on Thursday. Withers joined the Tyman board at the start of February.

----------

Signature Aviation PLC - Chief Executive Mark Johnstone buys 13,980 shares at 284.61p, worth GBP39,788, on Tuesday. Now holds 297,016 shares.

----------

Hiscox Ltd - Independent Non-Executive Director Colin Keogh buys 2,100 shares at GBP12.11, worth GBP25,441, on Tuesday. CFO Hamayou Akbar Hussain buys 1,300 shares at GBP12.22, worth GBP15,884, on Wednesday.

----------

Kingswood Holdings Ltd - Non-Executive Director David Hudd buys 200,000 shares at 24.5p, worth GBP49,000, on Wednesday. Purchase is his only holding.

----------

Hammerson PLC - Non-Executive Director Adam Metz buys 20,000 shares at GBP1.99, worth GBP39,800, on Wednesday.

----------

Eden Research PLC - Non-Executive Chair Lykele van der Broek buys 571,000 shares at 6.65p average price, worth GBP37,972, on Wednesday. Now holds 929,500 shares.

----------

Wizz Air Holdings PLC - Claude Bertrac, partner of Chief Corporate Officer Marion Geoffroy, buys 400 shares at GBP33.50, worth GBP13,400, on Monday.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 May 2024 14:34

Syncona notes Autolus's first quarter loss widens amid higher costs

(Alliance News) - Syncona Ltd on Friday noted that Autolus Therapeutics PLC reported an increased loss amid higher operating costs.

Read more
9 May 2024 13:58

IN BRIEF: Syncona's Freeline gets positive results for Gaucher disease

Syncona Ltd on Thursday - London-based investor in healthcare companies - Says UK portfolio company Freeline Therapeutics Ltd presents positive new data from its phase I and II Galileo-1 study of FLT201, its novel gene therapy candidate, in Gaucher disease. Says FLT201 demonstrates a favourable safety and tolerability profile, with no infusion reactions and no severe adverse events. Syncona notes that Gaucher disease is a "debilitating genetic disorder caused by a deficiency of the GCase enzyme". Syncona Chief Executive Officer Chris Hollowood says: "We are very encouraged by the data generated from FLT201 which demonstrates a favourable safety and tolerability profile and significant enzyme activity. We are confident this treatment has the potential to challenge the standard of care in Gaucher disease, where current treatments are life-long and do not fully alleviate the disease." Freeline Therapeutics is based in Stevenage, Hertfordshire.

Read more
9 May 2024 11:19

Syncona reports positive findings from investee Freeline

(Sharecast News) - Life science investor Syncona reported positive findings from its portfolio company Freeline Therapeutics on Thursday, after a phase one and two study of its gene therapy candidate for Gaucher disease, 'FLT20', showed encouraging results.

Read more
3 May 2024 09:14

LONDON BROKER RATINGS: Jefferies cuts AJ Bell; Deutsche likes ConvaTec

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning and Thursday:

Read more
11 Apr 2024 14:22

Syncona agrees to sell stake in investee company for GBP7.4 million

(Alliance News) - Syncona Ltd on Thursday said it has reached an agreement to sell one of its portfolio companies to US biotechnology firm, Century Therapeutics Inc.

Read more
4 Apr 2024 17:06

IN BRIEF: Syncona notes investee Achilles's annual loss narrows

Syncona Ltd - London-based investor in healthcare companies - Notes that the loss of investee and clinical-stage biopharmaceutical company Achilles Therapeutics PLC narrows by 2.7% to USD68.2 million in 2023 from USD71.1 million in 2022. General and administrative costs contract by 19% to USD17.0 million from USD21.1 million. According to Syncona's website, the company has a 25% stake in Achilles.

Read more
14 Mar 2024 14:16

Syncona portfolio company Autolus posts widened loss for 2023

(Alliance News) - Syncona Ltd on Thursday noted the 2023 results of one of its life science portfolio companies, which showed a widened loss and an increase in annual expenses.

Read more
12 Feb 2024 18:01

IN BRIEF: Freeline shareholders approve Syncona acquisition

Syncona Ltd - London-based investor in healthcare companies - Freeline Therapeutics Holdings PLC shareholders approve acquisition by Syncona.

Read more
8 Feb 2024 13:45

UPDATE: Syncona portfolio strengthens thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday said its portfolio company Autolus Therapeutics PLC has struck a deal to work with BioNTech to commercialise its CAR-T programmes.

Read more
8 Feb 2024 09:41

Syncona portfolio strengthens in third quarter thanks to Autolus

(Alliance News) - Syncona Ltd on Thursday reported a recent increase to the value of its portfolio, as the company said it was in a strong position to push forward its main life science companies.

Read more
8 Feb 2024 09:04

Syncona NAV grows in Q3

(Sharecast News) - Life sciences investor Syncona said on Thursday that its net asset value had grown in the three months ended 31 December, driven by a prioritisation of capital allocation across its portfolio to enable the delivery of key inflection points.

Read more
22 Jan 2024 12:19

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Read more
19 Jan 2024 08:36

Syncona says Freeline trial for Gaucher disease treatment positive

(Alliance News) - Syncona Ltd on Friday noted Freeline Therapeutics Holdings PLC's positive data for Gaucher disease treatment.

Read more
4 Dec 2023 09:37

IN BRIEF: Syncona notes Beacon's "encouraging" AGTC-501 trial data

Syncona Ltd - London-based investor in healthcare companies - Says portfolio company, Beacon Therapeutics has presented three-month data from the phase 2 Skyline trial of its viral vector-based gene therapy AGTC-501 in X-linked retinitis pigmentosa at the Floretina ICOOR 2023 Congress in Rome. Notes AGTC-501 shows an "encouraging efficacy profile", showing a "significant improvement" in retinal sensitivity. Adds that there are no clinically significant safety events related to AGTC-501.

Read more
27 Nov 2023 19:03

TRADING UPDATES: Molten Ventures completes raise; Saietta proposes one

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.